CYduct Diagnostics Inc (CYDX)

[Tradetalker]

McGrego, I found the doctor I talked to through a prior PR

http://www.otcmarkets.com/stock/SNDY/news/Solos-Endoscopy%2C-Inc.-Receives-Additional-Purchase-Orders-from-National-Cancer-Institute-and-National-Institute-of-Health-for-its-MammoView(TM)-Product-Line?id=17150&b=y

He's David Danforth, Jr., M.S., M.D., Surgery Branch Senior Investigator at the National Institute of Health. He was quoted in that PR: "The cytology retrieval kit which contains miniature brushes and a mini aspiratoris, in my opinion, the best method for retrieving cell samples from the lining of the mammary duct".

SNDY's endoscopy instruments have been at NIH for 6-8 years. Dr. Danforth has performed "hundreds" of procedures using SNDY instruments, and there have been several publications coming out of that work (http://www.ncbi.nlm.nih.gov/m/pubmed/17048242/).

I had emailed him 10 days ago and didn't expect a phone call - so was pretty surprised to get a call at my office. I thought he'd be curt, hurried - no way. He was open and conversational, and left no doubt about what Solos (he pronounced it Solas) had meant for his research and for breast cancer diagnosis in general. He said the imagery obtained was crisp, clear, striking. He said they can penetrate 10-15 cm, screening for lesions or other abnormalities. He said it has moved diagnosis and treatment far beyond where it had been 10-15 years ago. NIH's research focus is outlined in this link - he explained this in detail but I can't do it justice:

http://www.cancer.gov/clinicaltrials/search/view?cdrid=334479&version=HealthProfessional

He knew of Japanese and German firms who carried similar products, but they are far more expensive ($100K range); whereas Solos's system is around $30K. All of the NIH instruments, cameras, video equipment, etc., have been purchased from Solos. He said he did not know of anyone else carring these products in the US. Dr. Danforth said he enjoyed working with Solos, found them responsive, and said there instruments last a very long time. There was absolutely nothing in this conversation that cast any doubt on the quality, integrity, or status of the company. Obviously to the contrary - it confirmed to me that SNDY is critical to breast cancer research at NIH and elsewhere. Dr. Danforth gave me the names of several other MDs who are using endoscopy for more clinical breast cancer diagnosis; I'll be making some calls next week.

This was a really refreshing departure from all of the pps related angst on this board, mine included. SNDY has had and is having a real impact on a critical disease - I had heard that but now believe it. Solid long.